These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34508305)

  • 1. Research progress of DLX6-AS1 in human cancers.
    Luo Y; Ge P; Wang M; Chen H; Liu J; Wei T; Jiang Y; Qu J; Chen H
    Hum Cell; 2021 Nov; 34(6):1642-1652. PubMed ID: 34508305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer.
    Liang Y; Zhang CD; Zhang C; Dai DQ
    Gastric Cancer; 2020 Mar; 23(2):212-227. PubMed ID: 31463827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression.
    Zheng Q; Gu X; Yang Q; Chu Q; Dai Y; Chen Z
    Clin Chim Acta; 2021 Jun; 517():1-8. PubMed ID: 33607068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
    Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
    Huang Y; Ni R; Wang J; Liu Y
    Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.
    Wu DM; Zheng ZH; Zhang YB; Fan SH; Zhang ZF; Wang YJ; Zheng YL; Lu J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):237. PubMed ID: 31171015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region.
    Zhao H; Xu Q
    J Cell Mol Med; 2020 Nov; 24(21):12572-12584. PubMed ID: 32951317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA.
    Hu C; Liu K; Wang B; Xu W; Lin Y; Yuan C
    Curr Pharm Des; 2021; 27(9):1211-1218. PubMed ID: 33121401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1.
    Wu Q; Ma J; Meng W; Hui P
    Cancer Biol Ther; 2020; 21(1):17-25. PubMed ID: 31591939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
    Ding XZ; Zhang SQ; Deng XL; Qiang JH
    Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DLX6-AS1: a putative lncRNA candidate in multiple human cancers.
    Sheykhhasan M; Ahmadyousefi Y; Seyedebrahimi R; Tanzadehpanah H; Manoochehri H; Dama P; Hosseini NF; Akbari M; Eslami Farsani M
    Expert Rev Mol Med; 2021 Nov; 23():e17. PubMed ID: 34823630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.
    Zhao X; Wang J; Zhu R; Zhang J; Zhang Y
    Sci Rep; 2021 Oct; 11(1):21014. PubMed ID: 34697393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.
    Li D; Tang X; Li M; Zheng Y
    J Cell Biochem; 2019 Aug; 120(8):12290-12299. PubMed ID: 30805988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
    Zhao J; Liu HR
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis.
    Tian S; Liu J; Kong S; Peng L
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32785606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DLX6-AS1 accelerates cell proliferation through regulating miR-497-5p/SNCG pathway in prostate cancer.
    Zhu X; Ma X; Zhao S; Cao Z
    Environ Toxicol; 2021 Mar; 36(3):308-319. PubMed ID: 33035382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
    Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
    Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
    Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1.
    Li X; Zhang H; Wu X
    Gene; 2019 Feb; 686():1-7. PubMed ID: 30366080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.
    Ghafouri-Fard S; Najafi S; Hussen BM; Ganjo AR; Taheri M; Samadian M
    Front Cell Dev Biol; 2022; 10():746443. PubMed ID: 35281110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.